TransMedics Group Inc. (TMDX)
TransMedics (TMDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics: I'm More Bullish Than Ever
TransMedics remains a strong buy despite recent pullback, driven by seasonal weakness and changing transplant transport trends. TMDX's next-gen OCS heart and lung devices, along with kidney perfusion development, position TMDX for significant growth and market expansion. International markets, especially Europe, Middle East, and Australia, offer substantial growth opportunities and diversification beyond the US core business.
TransMedics: Upcoming Trials Are Critical
Concerns about seasonal weakness have dragged TransMedics' share price lower in recent weeks. While TransMedics' growth is moderating, there remains a sizeable growth opportunity within just the U.S. liver market. TMDX's next-gen heart and lung programs, kidney device development, and international expansion could also drive significant growth longer term.
TransMedics: Just Like The CEO, I'm Buying
TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company's unique OCS platform, integrated logistics, and service model create a strong moat, with next-gen products and international expansion as major growth catalysts. Financials are robust: Q2 2025 revenue grew 37.7% YoY, margins improved, and guidance was raised.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics: CEO Is Buying Shares Ahead Of A Potentially Concerning Q3
TransMedics delivered another strong beat-and-raise quarter, but Q3 faces a likely seasonal slowdown that could disappoint optimistic investors. The long-term thesis remains robust: best-in-class preservation, logistics, and expansion into new organs and geographies support significant growth potential. Despite recent CEO insider buying, the purchase is negligible relative to his holdings, and appears more symbolic than a signal of confidence.
Here's Why TransMedics (TMDX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why TransMedics (TMDX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average
TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX broke out above the 50-day moving average, suggesting a short-term bullish trend.
Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why TransMedics (TMDX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
